-
2
-
-
0033559213
-
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma
-
Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999;85:1261-8.
-
(1999)
Cancer
, vol.85
, pp. 1261-1268
-
-
Storniolo, A.M.1
Enas, N.H.2
Brown, C.A.3
Voi, M.4
Rothenberg, M.L.5
Schilsky, R.6
-
3
-
-
0025360261
-
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin
-
Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer. 1990;65:2207-12.
-
(1990)
Cancer
, vol.65
, pp. 2207-2212
-
-
Cullinan, S.1
Moertel, C.G.2
Wieand, H.S.3
Schutt, A.J.4
Krook, J.E.5
Foley, J.F.6
-
4
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
-
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris 3rd, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
-
5
-
-
79956219838
-
Locally advanced unresectable pancreatic cancer: induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: definitive results of the 2000-2001 FFCD/SFRO phase III trial
-
Barhoumi M, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Locally advanced unresectable pancreatic cancer: induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: definitive results of the 2000-2001 FFCD/SFRO phase III trial. Cancer Radiother. 2011;15:182-91.
-
(2011)
Cancer Radiother
, vol.15
, pp. 182-191
-
-
Barhoumi, M.1
Mornex, F.2
Bonnetain, F.3
Rougier, P.4
Mariette, C.5
Bouché, O.6
-
6
-
-
0033768608
-
A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
-
Oettle H, Arning M, Pelzer U, Arnold D, Stroszczynski C, Langrehr J, et al. A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol. 2000;11:1267-72.
-
(2000)
Ann Oncol
, vol.11
, pp. 1267-1272
-
-
Oettle, H.1
Arning, M.2
Pelzer, U.3
Arnold, D.4
Stroszczynski, C.5
Langrehr, J.6
-
7
-
-
0034025452
-
Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study
-
Matano E, Tagliaferri P, Libroia A, Damiano V, Fabbrocini A, De Lorenzo S, et al. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer. 2000;82:1772-5.
-
(2000)
Br J Cancer
, vol.82
, pp. 1772-1775
-
-
Matano, E.1
Tagliaferri, P.2
Libroia, A.3
Damiano, V.4
Fabbrocini, A.5
De Lorenzo, S.6
-
8
-
-
0036137690
-
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer
-
Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002;20:160-4.
-
(2002)
J Clin Oncol
, vol.20
, pp. 160-164
-
-
Cartwright, T.H.1
Cohn, A.2
Varkey, J.A.3
Chen, Y.M.4
Szatrowski, T.P.5
Cox, J.V.6
-
9
-
-
10744225818
-
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study
-
Stathopoulos GP, Syrigos K, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol. 2004;15:224-9.
-
(2004)
Ann Oncol
, vol.15
, pp. 224-229
-
-
Stathopoulos, G.P.1
Syrigos, K.2
Polyzos, A.3
Fountzilas, G.4
Rigatos, S.K.5
Ziras, N.6
-
10
-
-
0037208590
-
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial
-
Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol. 2003;21:66-8.
-
(2003)
J Clin Oncol
, vol.21
, pp. 66-68
-
-
Hess, V.1
Salzberg, M.2
Borner, M.3
Morant, R.4
Roth, A.D.5
Ludwig, C.6
-
11
-
-
12244296736
-
Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial
-
Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, et al. Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol. 2003;14:97-104.
-
(2003)
Ann Oncol
, vol.14
, pp. 97-104
-
-
Scheithauer, W.1
Schüll, B.2
Ulrich-Pur, H.3
Schmid, K.4
Raderer, M.5
Haider, K.6
-
12
-
-
0037080146
-
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer
-
Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002;20:582-7.
-
(2002)
J Clin Oncol
, vol.20
, pp. 582-587
-
-
Schilsky, R.L.1
Bertucci, D.2
Vogelzang, N.J.3
Kindler, H.L.4
Ratain, M.J.5
-
13
-
-
73949135518
-
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
-
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-8.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5513-5518
-
-
Cunningham, D.1
Chau, I.2
Stocken, D.D.3
Valle, J.W.4
Smith, D.5
Steward, W.6
-
14
-
-
34447536769
-
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
-
Park BB, Park JO, Lee HR, Lee J, Choi DW, Choi SH, et al. A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2007;60:489-94.
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 489-494
-
-
Park, B.B.1
Park, J.O.2
Lee, H.R.3
Lee, J.4
Choi, D.W.5
Choi, S.H.6
-
15
-
-
0030049697
-
Phase II study of gemcitabine in patients with advanced pancreatic cancer
-
Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73:101-5.
-
(1996)
Br J Cancer
, vol.73
, pp. 101-105
-
-
Carmichael, J.1
Fink, U.2
Russell, R.C.3
Spittle, M.F.4
Harris, A.L.5
Spiessi, G.6
-
16
-
-
4644327989
-
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
-
Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-83.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3776-3783
-
-
Rocha Lima, C.M.1
Green, M.R.2
Rotche, R.3
Miller Jr, W.H.4
Jeffrey, G.M.5
Cisar, L.A.6
-
17
-
-
20644464360
-
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial
-
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-16.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3509-3516
-
-
Louvet, C.1
Labianca, R.2
Hammel, P.3
Lledo, G.4
Zampino, M.G.5
André, T.6
-
18
-
-
33749071359
-
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
-
Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006;24:4441-7.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4441-4447
-
-
Abou-Alfa, G.K.1
Letourneau, R.2
Harker, G.3
Modiano, M.4
Hurwitz, H.5
Tchekmedyian, N.S.6
-
19
-
-
27144530079
-
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
-
Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639-45.
-
(2005)
Ann Oncol
, vol.16
, pp. 1639-1645
-
-
Oettle, H.1
Richards, D.2
Ramanathan, R.K.3
van Laethem, J.L.4
Peeters, M.5
Fuchs, M.6
-
20
-
-
2342645506
-
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
-
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-8.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1430-1438
-
-
Van Cutsem, E.1
van de Velde, H.2
Karasek, P.3
Oettle, H.4
Vervenne, W.L.5
Szawlowski, A.6
-
21
-
-
34250180939
-
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
-
Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212-7.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2212-2217
-
-
Herrmann, R.1
Bodoky, G.2
Ruhstaller, T.3
Glimelius, B.4
Bajetta, E.5
Schüller, J.6
-
22
-
-
58149382070
-
Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy
-
Harsha HC, Jimeno A, Molina H, Mihalas AB, Goggins MG, Hruban RH, et al. Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res. 2008;7:4651-8.
-
(2008)
J Proteome Res
, vol.7
, pp. 4651-4658
-
-
Harsha, H.C.1
Jimeno, A.2
Molina, H.3
Mihalas, A.B.4
Goggins, M.G.5
Hruban, R.H.6
-
23
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
Figer, A.4
Hecht, J.R.5
Gallinger, S.6
-
24
-
-
73949107880
-
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment
-
Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009;27:5660-9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5660-5669
-
-
Philip, P.A.1
Mooney, M.2
Jaffe, D.3
Eckhardt, G.4
Moore, M.5
Meropol, N.6
|